Medical Oncology

, Volume 17, Issue 2, pp 77–84 | Cite as

Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?

  • J Bladé
  • J Esteve
Review

Abstract

Interferon-α (IFN-α) generally inhibits myeloma cell growth. However, a growth stimulatory effect for myeloma cells has also been reported. In patients with untreated multiple myeloma (MM) IFN-α, used as a single agent, produced an objective response rate ranging from 10 to 25%. In previously untreated patients: (1) the time to response is short, (2) the median duration of response is similar to the duration of response observed in patients given chemotherapy, and (3) the patients who are more likely to benefit are those with IgA myeloma type. Concerning the results of IFN-α given as a single agent in relapsing and resistant MM, they are poor, with a response rate ranging between 10–20%. The combination of high-dose glucocorticoids and IFN-α for relapsing/resistant patients produced controversial results. Some studies showed an increased response rate and/or longer survival with chemotherapy plus IFN-α versus chemotherapy alone in previously untreated patients. In contrast, most reports did not show a significant increase in response rate or survival benefit by adding IFN-α to the initial chemotherapy. Perhaps the most encouraging role for IFN in MM is as maintenance therapy in patients responding to first line treatment (ie conventional chemotherapy followed or not by high-dose intensification/autotransplantation). In spite of that, several reports failed to show longer response duration. The majority of studies have shown a modest but significant prolongation in response duration in favour of the IFN arm. However, most of these studies have failed to show a significant survival advantage with IFN maintenance. A meta-analysis, by the Myeloma Trialists' Collaborative Group in Oxford, based on the individual data from 4012 patients included in 24 randomized trials (induction and/or maintenance) has shown that IFN produced a moderate improvement in relapse-free survival and a minor improvement in overall survival. In summary, the only role of IFN in MM is as maintenance treatment after a response is achieved. However, looking at the published data, it seems that the vast majority of patients do not benefit from IFN maintenance, while a small proportion of them, in the range of 5–10%,

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ludwig CU, Durie BGM, Salmon SE, Moon TE. Tumor growth stimulation in vitro by interferons.Eur J Cancer Clin Oncol 1983;19: 1625–1632.PubMedCrossRefGoogle Scholar
  2. 2.
    Brenning G. The in vitro effect of leucocyte alfa-interferon on human myeloma cells in a semisolid agar culture system.Scand J Haematol 1985;35: 178–185.PubMedCrossRefGoogle Scholar
  3. 3.
    Schwabe Met al. Disruption by interferon-alpha of an interleukin 6 growth loop in IL-6 dependent U266 myeloma cells by homologous and heterologous downregulation of the IL-6 receptor alpha and beta chains.J Clin Invest 1994;94: 2317–2325.PubMedGoogle Scholar
  4. 4.
    Einhorn S, Blomgren H, Strander H. Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leucocyte interferon.Int J Cancer 1978;22: 405–412.PubMedCrossRefGoogle Scholar
  5. 5.
    Herberman RR, Ortaldo JR, Bonnard GD. Augmention by interferon of human natural antibody-dependent cell-mediated cytotoxicity.Nature 1978;277: 275–277.Google Scholar
  6. 6.
    Toy JL. The interferons.Clin Exp Immunol 1983;54: 1–13.PubMedGoogle Scholar
  7. 7.
    Stiehm Er, Kronenberg LH, Rosenblatt HM, Bryson Y, Merigan TC. Interferon: immunobiology and clinical significance.Ann Intern Med 1982;96: 80–93.PubMedGoogle Scholar
  8. 8.
    Tanaka Het al. Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells.Blood 1989;74: 1718–1722.PubMedGoogle Scholar
  9. 9.
    McGinnes K, Penny R. Effect of interferon on the in vitro synthesis of paraprotein by plasma cells in myeloma.Acta Haematol 1988;79: 72–76.PubMedGoogle Scholar
  10. 10.
    Shimizu Set al. Establishment of two interleukin-6 (B-cell stimulatory factor 2/interferon-beta 2) dependent human bone marrow derived myeloma cell lines.J Exp Med 1989;169: 334–339.CrossRefGoogle Scholar
  11. 11.
    Jourdan Met al. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.J Immunol 1991;147: 4402–4407.PubMedGoogle Scholar
  12. 12.
    Jelinek Det al. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.J Clin Invest 1997;99: 447–456.PubMedCrossRefGoogle Scholar
  13. 13.
    Blaé J, López-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukemia under interferon-alpha therapy.Br J Haematol 1991;79: 523–525.Google Scholar
  14. 14.
    Sawamura Net al. Plasma cell leukemia with alpha-interferon therapy in myeloma.Br J Haematol 1992;82: 631.PubMedGoogle Scholar
  15. 15.
    Portier Met al. Gamma-interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro.Blood 1993;81: 3076–3082.PubMedGoogle Scholar
  16. 16.
    Palumbo Aet al. Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells.Br J Haematol 1994;86: 726–732.PubMedGoogle Scholar
  17. 17.
    Quesada Ret al. Recombinant interferon-gamma in hairy cell leukemia, multiple myeloma and Waldenström's macroglobulinemia.Am J Hematol 1988;29: 1–4.PubMedCrossRefGoogle Scholar
  18. 19.
    Ohno Ret al. Treatment of multiple myeloma with recombinant human leukocyte A interferon.Cancer Treat Rep 1985;60: 1433–1435.Google Scholar
  19. 20.
    Quesada JRet al. Treatment of multiple myeloma with recombinant alpha-interferon.Blood 1986;67: 275–278.PubMedGoogle Scholar
  20. 21.
    Eastern Cooperative Study Group on Monoclonal Gammopathies (ECOG). Low-dose interferon-alpha in stage-1 multiple myeloma and in IgM monoclonal gammopathy.Ann Hematol 1992;64: 123–127.CrossRefGoogle Scholar
  21. 22.
    Ahre Aet al. High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS).Eur J Haematol 1988;41: 123–130.PubMedCrossRefGoogle Scholar
  22. 23.
    Ahre Aet al. High doses of natural alpha-interferon (alpha-IFN) in the treatment of multiple myeloma. A pilot study from the Myeloma Group of Central Sweden (MGCS).Eur J Haematol 1988;41: 123–130.PubMedCrossRefGoogle Scholar
  23. 24.
    Ludwig Het al. Recombinant interferon-alpha-2c versus polychemotherapy (VCMP) for treatment of multiple myeloma: a prospective randomized trial.Eur J Cancer Clin Oncol 1986;22: 111–116.CrossRefGoogle Scholar
  24. 25.
    Costanzi JJet al. Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.J Clin Oncol 1985;3: 654–659.PubMedGoogle Scholar
  25. 26.
    Ohno R, Kimura K. Treatment of multiple myeloma with recombinant interferon alpha-2a.Cancer 1986;57: 1685–1688.PubMedCrossRefGoogle Scholar
  26. 27.
    Wagstaff J, Loynds P, Scarffe JH. Phase II study of rDNA human alpha-2 interferon in multiple myeloma.Cancer Treat Rep 1985;69: 495–498.PubMedGoogle Scholar
  27. 28.
    Case DCet al. Phase II study of rDNA alpha-2-interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase.Cancer Treat Rep 1986;70: 1251–1254.PubMedGoogle Scholar
  28. 29.
    San Miguel JFet al. Combination of interferon and dexamethasone in refractory multiple myeloma.Hematol Oncol 1990;8: 185–189.PubMedCrossRefGoogle Scholar
  29. 30.
    Alexanian R, Barlogie B, Gutterman J. Alpha-interferon combination therapy of resistant myeloma.M J Clin Oncol 1991;14: 188–192.CrossRefGoogle Scholar
  30. 31.
    Gertz M, Kalish LA, Kyle RA. Phase III study comparing vincristine, doxorubicin (adriamycin) and dexmethasone (VAD) chemotherapy with VAD plus recombinant interferon alpha-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.Am J Clin Oncol 1995;18: 475–481.PubMedGoogle Scholar
  31. 32.
    Cooper MR, Welander CE. Interferons in the treatment of multiple myeloma.Cancer 1987;59: 594–600.PubMedCrossRefGoogle Scholar
  32. 33.
    Cooper MRet al. Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I–II trial.Cancer Treat Rep 1986;70: 473–476.PubMedGoogle Scholar
  33. 34.
    Oken MMet al. Chemotherapy plus interferon (rIFN) in the treatment of multiple myeloma.Proc Am Soc Clin Oncol 1990;9: 288.Google Scholar
  34. 35.
    Montuoro Aet al. Alpha-2a interferon/Melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.Br J Haematol 1990;76: 365–368.PubMedGoogle Scholar
  35. 36.
    Österborget al. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.Blood 1993;81: 1428–1434.PubMedGoogle Scholar
  36. 37.
    Oken MMet al. The effect of adding interferon (rINF-alpha2) or high-dose cyclophosphamide to BVMCP to treat multiple myeloma: results from an ECOG phase III trial.Blood 1995;86 (Suppl. 1): 441a.Google Scholar
  37. 38.
    Cooper MRet al. A randomized trial comparing melphalan/prednisone with or without interferon alpha-2b in newly diagnosed patients with muliple myeloma: a Cancer and Acute Leukemia Group B study.J Clin Oncol 1993;11: 155–160.PubMedGoogle Scholar
  38. 39.
    Casassus Phet al. Randomized comparison of interferon-alpha with VCMP/VBAP regimen as the induction phase of untreated multiple myeloma: results of the KIF multi-centre trial.Blood 1995;86 (Suppl. 1): 441a.Google Scholar
  39. 40.
    Capnist Get al. Impact of interferon a induction chemotherapy and maintenance treatment for multiple myeloma. Preliminary results of a multicenter study by the Italian non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).Acta Oncol 1994;33: 527–529.PubMedCrossRefGoogle Scholar
  40. 41.
    Ludwig Het al. Interferon alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.Ann Oncol 1995;6: 467–476.PubMedGoogle Scholar
  41. 42.
    The Nordic Myeloma Study Group. Interferon-alpha-2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a Nordic randomized controlled trial.Ann Intern Med 1996;124: 212–222.Google Scholar
  42. 43.
    Abrahamson GMet al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma.Br J Haematol 1996;94: 659–664.PubMedCrossRefGoogle Scholar
  43. 44.
    Joshua DEet al. Australian Leukemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma.Br J Haematol 1997;97: 38–45.PubMedCrossRefGoogle Scholar
  44. 45.
    Dimopoulos MA, Weber D, Delasalle KB, Alexanian R. Combintion therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.Cancer 1993;72: 2589–2592.PubMedCrossRefGoogle Scholar
  45. 46.
    Wheatley K (on behalf of the Myeloma Trialists' Collaborative Group). Which myeloma patients benefit from interferon therapy? An overview of 24 randomized trials with 4000 patients.Br J Haematol 1998;102: 140.Google Scholar
  46. 47.
    Durie BGM, Rusell DH, Salmon SE. Reappraisal of plateau phase in multiple myeloma.Lancet 1980;2: 65–67.PubMedCrossRefGoogle Scholar
  47. 48.
    Belch Aet al. A randomized trial of maintenance versus no maintenance with melphalan and prednisone in responding multiple myeloma patients.Br J Cancer 1988;57: 94–99.PubMedGoogle Scholar
  48. 49.
    Bergsagel DEet al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia.N Engl J Med 1979;301: 743–748.PubMedCrossRefGoogle Scholar
  49. 50.
    Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase?Br J Haematol 1994;89: 667–671.Google Scholar
  50. 51.
    Bladé J, Kyle RA. Monoclonal gammopathies of undetermined significance. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (eds)Myeloma. Biology and Management. Second edn. Oxford University Press: Oxford 1998; pp 513–544.Google Scholar
  51. 52.
    Kyle RA, Greipp PR. Smoldering multiple myeloma.N Engl J Med 1980;302: 1347–1349.PubMedCrossRefGoogle Scholar
  52. 53.
    Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt myeloma.Hemaltol Oncol Clin North Am 1997;11: 71–78.CrossRefGoogle Scholar
  53. 54.
    Peest Det al. Cytokine therapy in multiple myeloma.Br J Haematol 1996;94: 425–432.PubMedCrossRefGoogle Scholar
  54. 55.
    Mandelli Fet al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy.N Engl J Med 1990;322: 1430–1434.PubMedCrossRefGoogle Scholar
  55. 56.
    Westin Jet al. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study.Br J Haematol 1995;89: 561–568.PubMedGoogle Scholar
  56. 57.
    Browman GPet al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol 1995;13: 2354–2360.PubMedGoogle Scholar
  57. 58.
    Bladé Jet al. Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from the Spanish Cooperative Group PETHEMA.Leukemia 1998;12: 1144–1148.PubMedCrossRefGoogle Scholar
  58. 59.
    Salmon SEet al. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study.J Clin Oncol 1994;12: 2405–2414.PubMedGoogle Scholar
  59. 60.
    Peest Det al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma: a prospective trial of the German Myeloma Treatment Group.Eur J Cancer 1995;31A: 146–151.PubMedCrossRefGoogle Scholar
  60. 61.
    Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, MacLennan ICM. MRC trial of alpha-2 interferon maintenance therapy in first plateau phase of multiple myeloma.Br J Haematol 1998;101: 195–202.PubMedCrossRefGoogle Scholar
  61. 62.
    Grosbois Bet al. Interferon maintenance therapy in multiple myeloma patients achieving plateau phase after induction therapy: multicenter randomized trial.Blood 1997;90 (Suppl. 1): 356a.Google Scholar
  62. 63.
    Offidani Met al. Two dosage interferon-alpha-2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial.Haematologica 1998;83: 40–47.PubMedGoogle Scholar
  63. 64.
    Cunningham Det al. A randomized trial of maintenance therapy with Intron A following high-dose melphalan and ABMT in myeloma.Proc Am Soc Clin Oncol 1993;12: 364.Google Scholar
  64. 65.
    Cunningham Det al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.Br J Haematol 1998;102: 495–502.PubMedCrossRefGoogle Scholar
  65. 66.
    Björkstrand Bet al. 2522 autotransplants in multiple myeloma. A registry study from the European group for blood and marrow transplantation (EBMT).Blood 1997;90 (Suppl. 1): 419a.Google Scholar
  66. 67.
    Alegre Aet al. Autologous peripheral blood stemcell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry.Bone Marrow Transplant 1998;21: 133–140.PubMedCrossRefGoogle Scholar
  67. 68.
    Harouseau JLet al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma.Blood 1995;85: 3077–3085.Google Scholar
  68. 69.
    Palumbo Aet al. Multiple myeloma: Intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids.Eur J Haematol 1992;49: 93–97.PubMedCrossRefGoogle Scholar
  69. 70.
    Boccardoro Met al. Melphalan and prednisone (MP) followed by interferon plus dexamethasone maintenance therapy improves remission duration of myeloma patients.Blood 1997;90 (Suppl. 1): 355a.Google Scholar
  70. 71.
    Salmon SEet al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group study.J Clin Oncol 1998;16: 890–896.PubMedGoogle Scholar
  71. 72.
    Berenson J, Crowley J, Barlogie B, Salmon S. Alternate day oral prednisone maintenance therapy improves progression-free survival and overall survival in multiple myeloma patients.Blood 1998;92 (Suppl. 1): 318a.Google Scholar
  72. 73.
    Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone+alpha-interferon.Br J Haematol 1996;94: 324–332.PubMedCrossRefGoogle Scholar
  73. 74.
    Ludwig H, Fritz E, Neuda J, Durie BGM. Patient preferences for interferon alpha in multiple myeloma.J Clin Oncol 1997;15: 1672–1679.PubMedGoogle Scholar
  74. 75.
    Pulsoni Aet al. The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after.Blood 1998;92: 2184–2186.PubMedGoogle Scholar

Copyright information

© Macmillan Publishers Ltd All rights reserved 2000

Authors and Affiliations

  • J Bladé
    • 1
  • J Esteve
    • 1
  1. 1.Department of Hematology, IDIBAPS, (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Hospital ClinicUniversity of BarcelonaBarcelonaSpain

Personalised recommendations